| Literature DB >> 29238454 |
Seyed Fazlollah Mousavi1, Bahman Mirzaei1, Bahareh Shaghaghi1, Pantea Jalali1, Tahereh Setayesh1, Seyed Hamid Moosavi1.
Abstract
BACKGROUND AND OBJECTIVES: Designing control and therapeutic policies for antibiotic resistant Streptococcus pneumoniae, which is an important causative agent of several invasive and noninvasive infectious diseases and its carriage rates, has been described as the main target in World Health Organization (WHO). The present study was conducted to determine antibiotic resistance pattern, evaluate biofilm forming ability in S. pneumoniae isolates, and find the genetic relationship between cultured strains.Entities:
Keywords: Biofilm; Clonal diversity; PFGE; Streptococcus pneumoniae
Year: 2017 PMID: 29238454 PMCID: PMC5723971
Source DB: PubMed Journal: Iran J Microbiol ISSN: 2008-3289
Fig. 1.Molecular identification of S. Pneumoniae isolates by cpsA gene
M, 100bp DNA ladder; Lane 1, Control strain (S. pneumonia ATCC6305); Lane 2- 14alpha–hemolytic and optochin susceptible isolated strain
Fig. 2.Dendrogram of 8 (Center 1) and 22 (Center 2) Pulsed field fel electrophoresis profiles from 15 and 31 S. pneumoniae isolates
Fig. 3.Dendrogram of 14 (Center 3) and 8 (Center 4) Pulsed field gel electrophoresis profiles from 20 and 10 S. pneumoniae isolates
Susceptibility of S. pneumoniae isolates to various antibiotics obtained by disk diffusion method
| Tetracycline (30μg) | 5 | 14 | 81 |
| Bacitracin (10U) | - | - | 100 |
| amoxicillin-clavulanic acid (20+10 μg) | 26 | - | 74 |
| Erythromycin (15μg) | 86 | - | 14 |
| Gentamycin (10μg) | 94 | 1.3 | 4.7 |
| Nalidixic Acid (30μg) | 100 | - | - |
| Tobramycin (10μg) | 98.7 | - | 1.3 |
| Azithromycin (15μg) | 86 | - | 14 |
| Oxacillin (1μg) | 100 | - | - |
| Rifampicin (5μg) | - | - | 100 |
Fig. 4.Biofilm forming ability of all isolates,*Non-biofilm former: The strain does not have any ability to form biofilm. **Weak-Biofilm Former: The strain has a weak ability to form biofilm (0.120